New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness?
Apostolakis
Stavros
S
University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, England.
Shantsila
Eduard
E
Lip
Gregory Y H
GY
D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D000069604:Dabigatran; D017850:Economics, Pharmaceutical; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000069552:Rivaroxaban; D013876:Thiophenes / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000191:economics
D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011725:Pyridines; D013876:Thiophenes; D000069552:Rivaroxaban; D000069604:Dabigatran